Cargando…
Lenvatinib in multimodal therapy for unresectable radioactive iodine‐naïve differentiated thyroid cancer: A case report with literature review
BACKGROUND: Patients with unresectable or metastatic differentiated thyroid carcinoma (DTC) are rare and require individualized therapy. This may require approaches not typically used in resectable disease. We report a patient treated with lenvatinib and external beam radiation therapy. CASE: An 87‐...
Autores principales: | Kim, Hugh Andrew Jinwook, Nichols, Anthony Charles, Rachakonda, Ramanamurthy, Inculet, Richard, Sathya, Jinka, Rachinsky, Irina, Winquist, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575506/ https://www.ncbi.nlm.nih.gov/pubmed/35715880 http://dx.doi.org/10.1002/cnr2.1654 |
Ejemplares similares
-
Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model
por: Suzuki, Kensuke, et al.
Publicado: (2022) -
Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018) -
Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease
por: Wolfson, Robert M., et al.
Publicado: (2016) -
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022) -
Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2023)